We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 11 of 373 for:    "Pulmonary Emphysema"

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 17, 2004
Last Update Posted: March 6, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Aeris Therapeutics
The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.

Condition Intervention Phase
Pulmonary Emphysema Biological: BLVR Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Heterogeneous Emphysema

Resource links provided by NLM:

Further study details as provided by Aeris Therapeutics:

Primary Outcome Measures:
  • SAEs - Safety [ Time Frame: 1 year post treatment ]

Secondary Outcome Measures:
  • PFTs [ Time Frame: 12 weeks post treatment ]
  • Dyspnea [ Time Frame: 12 weeks post treatment ]
  • Exercise capacity [ Time Frame: 12 weeks post treatment ]
  • QOL [ Time Frame: 12 weeks post treatment ]

Enrollment: 6
Study Start Date: April 2005
Study Completion Date: June 2007
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single
Treatment with BLVR
Biological: BLVR
10 mL Hydrogel

Detailed Description:

Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky.

Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced emphysema
  • Limited exercise capacity and persistent symptoms despite medical therapy
  • Age between 18 and 75
  • No significant heart, kidney or liver disease
  • Willingness and ability to tolerate bronchoscopy
  • No prior Lung Volume Reduction Surgery or Lung Transplantation
  • Screening test results indicating that the procedure is appropriate
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00085852

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Caritas St Elizabeth's Medical Center
Boston, Massachusetts, United States, 02135
Sponsors and Collaborators
Aeris Therapeutics
Principal Investigator: John J. Reilly, MD Brigham and Women's Hospital
  More Information

Responsible Party: Edward P Ingenito, MD, PhD, Medical Director & CSO, Aeris Therapeutics Inc
ClinicalTrials.gov Identifier: NCT00085852     History of Changes
Other Study ID Numbers: C04-001
IRB Protocol # 2003-P-002171
First Submitted: June 15, 2004
First Posted: June 17, 2004
Last Update Posted: March 6, 2008
Last Verified: February 2008

Keywords provided by Aeris Therapeutics:
chronic obstructive pulmonary disease
lung volume reduction

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases